<p>B. Riley Wealth Advisors Inc. 在第二季度购买了 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的新股份，根据其最近向证券交易委员会 (SEC) 提交的 13F 表格。该机构投资者购买了 4,141 股该制药公司的股票，价值约为 1,844,000 美元。</p>
<ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下创造现金</li>
</ul>
<p>其他几家大型投资者最近也增加或减少了对 VRTX 的持股。Activest Wealth Management 在第一季度获得了价值约 25,000 美元的 Vertex Pharmaceuticals 新股份。Access Investment Management LLC 在第二季度购买了价值约 27,000 美元的 Vertex Pharmaceuticals 新股份。Legacy Investment Solutions LLC 在第二季度获得了价值约 29,000 美元的 Vertex Pharmaceuticals 新职位。Flaharty Asset Management LLC 在第一季度购买了价值 32,000 美元的 Vertex Pharmaceuticals 新职位。最后，American National Bank &amp; Trust 在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 515.4%。American National Bank &amp; Trust 目前拥有 80 股该制药公司的股票，价值 36,000 美元，此前在上个季度又购买了 67 股。90.96% 的股票由机构投资者和对冲基金持有。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 警报：</p>
<h2>Vertex Pharmaceuticals 股票上涨 1.4%</h2>
<p>VRTX 股票周一开盘价为 452.04 美元。该公司的 50 日移动平均线为 426.51 美元，200 日移动平均线为 425.47 美元。该公司的市值为 1,146.9 亿美元，市盈率为 31.88，贝塔值为 0.32。Vertex Pharmaceuticals Incorporated 的 12 个月低点为 362.50 美元，12 个月高点为 519.68 美元。</p>
<ul>
<li>2025 年最佳生物技术股票</li>
</ul>
<p>Vertex Pharmaceuticals (NASDAQ:VRTX - 获取免费报告) 最近于 11 月 3 日发布了季度财报。该制药公司报告本季度每股收益为 4.80 美元，超出分析师一致预期的 4.58 美元，超出幅度为 0.22 美元。该季度的营业收入为 30.8 亿美元，而一致预期为 30.5 亿美元。Vertex Pharmaceuticals 的净利润率为 31.35%，股本回报率为 23.51%。与去年同期相比，Vertex Pharmaceuticals 本季度的收入增长了 11.0%。在去年同期，该公司的每股收益为 4.38 美元。研究分析师平均预计 Vertex Pharmaceuticals Incorporated 本年度将发布 15.63 的每股收益。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家券商最近对 VRTX 发布了报告。Leerink Partners 在 9 月 25 日的研究报告中将 Vertex Pharmaceuticals 的评级从 “持有” 上调至 “强力买入”。花旗集团在 10 月 2 日的报告中将 Vertex Pharmaceuticals 的目标价从 550.00 美元上调至 575.00 美元，并给予该股票 “买入” 评级。巴克莱在 11 月 4 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 408.00 美元上调至 414.00 美元，并给予该公司 “等权重” 评级。加拿大皇家银行在 11 月 4 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 423.00 美元下调至 415.00 美元，并对该股票设定了 “行业表现” 评级。最后，Stifel Nicolaus 在 11 月 4 日的报告中将 Vertex Pharmaceuticals 的目标价从 455.00 美元下调至 445.00 美元，并对该股票设定了 “持有” 评级。三位股票研究分析师对该股票给予了强力买入评级，十五位给予了买入评级，十位给予了持有评级。根据 MarketBeat.com 的数据，Vertex Pharmaceuticals 目前的共识评级为 “适度买入”，共识目标价为 498.42 美元。</p>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p><strong>查看我们关于 Vertex Pharmaceuticals 的最新研究报告</strong></p>
<h2>Vertex Pharmaceuticals 的内部交易</h2>
<p>在 Vertex Pharmaceuticals 的其他新闻中，执行副总裁 Charles F. Wagner, Jr. 于 12 月 3 日出售了 14,000 股公司的股票，交易发生在该日。股票以平均价格 456.00 美元出售，总价值为 6,384,000.00 美元。出售完成后，该执行副总裁直接持有 37,725 股公司的股票，价值 17,202,600 美元。此次交易使其持股减少了 27.07%。该交易已在 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，董事长 Jeffrey M. Leiden 于 12 月 3 日在一笔交易中出售了 63,781 股公司的股票。股票以平均价格 449.20 美元出售，总交易额为 28,650,425.20 美元。交易完成后，董事长在公司持有 24,026 股，价值 10,792,479.20 美元。这代表其持股减少了 72.64%。该销售的 SEC 文件提供了更多信息。过去九十天内，内部人士共出售了价值 67,326,816 美元的 151,073 股公司股票。公司内部人士持有公司股票的 0.20%。</p>
<h2>关于 Vertex Pharmaceuticals</h2>
<p>(免费报告)</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化 (CF) 的疗法。它为至少 2 岁或以上的 CF 患者提供 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者提供 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者提供 ORKAMBI；以及为 1 岁或以上的 CF 患者提供 ivacaftor 的 KALYDECO。</p>
<h2>特色故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>如何判断一只股票是否支付股息以及何时支付</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了实施阶段</li>
<li>CD 计算器：定期存款计算器</li>
<li>在 10 年期国债利率上升时购买的 3 只金融股票</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场意识到之前购买……而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VERX

RILY

福泰制药

<p>B. Riley Wealth Advisors Inc. 在第二季度收购了 4,141 股 Vertex Pharmaceuticals，价值约为 1,844,000 美元。此项收购已在他们向 SEC 提交的 13F 表格中报告。Vertex Pharmaceuticals 的股票表现良好，最近价格上涨，并且财报表现积极。几位分析师给予了积极的评级，该公司的共识评级为 “适度买入”，目标价格为 498.42 美元</p>

<p>B. Riley Wealth Advisors Inc. bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,141 shares of the pharmaceutical company's stock, valued at approximately $1,844,000.</p>
<div class="lb-trans"><p>B. Riley Wealth Advisors Inc. 在第二季度购买了 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的新股份，根据其最近向证券交易委员会 (SEC) 提交的 13F 表格。该机构投资者购买了 4,141 股该制药公司的股票，价值约为 1,844,000 美元。</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下创造现金</li>
</ul>
</div><p>Several other large investors have also recently added to or reduced their stakes in VRTX. Activest Wealth Management acquired a new stake in shares of Vertex Pharmaceuticals in the 1st quarter worth about $25,000. Access Investment Management LLC bought a new stake in Vertex Pharmaceuticals in the second quarter worth about $27,000. Legacy Investment Solutions LLC acquired a new position in Vertex Pharmaceuticals in the second quarter worth approximately $29,000. Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals in the first quarter valued at $32,000. Finally, American National Bank &amp; Trust lifted its position in shares of Vertex Pharmaceuticals by 515.4% during the 2nd quarter. American National Bank &amp; Trust now owns 80 shares of the pharmaceutical company's stock valued at $36,000 after acquiring an additional 67 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也增加或减少了对 VRTX 的持股。Activest Wealth Management 在第一季度获得了价值约 25,000 美元的 Vertex Pharmaceuticals 新股份。Access Investment Management LLC 在第二季度购买了价值约 27,000 美元的 Vertex Pharmaceuticals 新股份。Legacy Investment Solutions LLC 在第二季度获得了价值约 29,000 美元的 Vertex Pharmaceuticals 新职位。Flaharty Asset Management LLC 在第一季度购买了价值 32,000 美元的 Vertex Pharmaceuticals 新职位。最后，American National Bank &amp; Trust 在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 515.4%。American National Bank &amp; Trust 目前拥有 80 股该制药公司的股票，价值 36,000 美元，此前在上个季度又购买了 67 股。90.96% 的股票由机构投资者和对冲基金持有。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 警报：</p>
</div><h2>Vertex Pharmaceuticals Stock Up 1.4%</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票上涨 1.4%</h2>
</div><p>VRTX stock opened at $452.04 on Monday. The company has a 50 day moving average of $426.51 and a two-hundred day moving average of $425.47. The company has a market cap of $114.69 billion, a price-to-earnings ratio of 31.88 and a beta of 0.32. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.68.</p>
<div class="lb-trans"><p>VRTX 股票周一开盘价为 452.04 美元。该公司的 50 日移动平均线为 426.51 美元，200 日移动平均线为 425.47 美元。该公司的市值为 1,146.9 亿美元，市盈率为 31.88，贝塔值为 0.32。Vertex Pharmaceuticals Incorporated 的 12 个月低点为 362.50 美元，12 个月高点为 519.68 美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技术股票</li>
</ul>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, topping analysts' consensus estimates of $4.58 by $0.22. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. Vertex Pharmaceuticals's revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the prior year, the business posted $4.38 earnings per share. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals (NASDAQ:VRTX - 获取免费报告) 最近于 11 月 3 日发布了季度财报。该制药公司报告本季度每股收益为 4.80 美元，超出分析师一致预期的 4.58 美元，超出幅度为 0.22 美元。该季度的营业收入为 30.8 亿美元，而一致预期为 30.5 亿美元。Vertex Pharmaceuticals 的净利润率为 31.35%，股本回报率为 23.51%。与去年同期相比，Vertex Pharmaceuticals 本季度的收入增长了 11.0%。在去年同期，该公司的每股收益为 4.38 美元。研究分析师平均预计 Vertex Pharmaceuticals Incorporated 本年度将发布 15.63 的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of brokerages have recently issued reports on VRTX. Leerink Partnrs raised Vertex Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, September 25th. Citigroup boosted their price objective on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, October 2nd. Barclays upped their price objective on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the company an &#34;equal weight&#34; rating in a research note on Tuesday, November 4th. Royal Bank Of Canada dropped their target price on shares of Vertex Pharmaceuticals from $423.00 to $415.00 and set a &#34;sector perform&#34; rating on the stock in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus cut their price target on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a &#34;hold&#34; rating on the stock in a report on Tuesday, November 4th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $498.42.</p>
<div class="lb-trans"><p>多家券商最近对 VRTX 发布了报告。Leerink Partners 在 9 月 25 日的研究报告中将 Vertex Pharmaceuticals 的评级从 “持有” 上调至 “强力买入”。花旗集团在 10 月 2 日的报告中将 Vertex Pharmaceuticals 的目标价从 550.00 美元上调至 575.00 美元，并给予该股票 “买入” 评级。巴克莱在 11 月 4 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 408.00 美元上调至 414.00 美元，并给予该公司 “等权重” 评级。加拿大皇家银行在 11 月 4 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 423.00 美元下调至 415.00 美元，并对该股票设定了 “行业表现” 评级。最后，Stifel Nicolaus 在 11 月 4 日的报告中将 Vertex Pharmaceuticals 的目标价从 455.00 美元下调至 445.00 美元，并对该股票设定了 “持有” 评级。三位股票研究分析师对该股票给予了强力买入评级，十五位给予了买入评级，十位给予了持有评级。根据 MarketBeat.com 的数据，Vertex Pharmaceuticals 目前的共识评级为 “适度买入”，共识目标价为 498.42 美元。</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p><strong>View Our Latest Research Report on Vertex Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Vertex Pharmaceuticals 的最新研究报告</strong></p>
</div><h2>Insider Transactions at Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 的内部交易</h2>
</div><p>In other Vertex Pharmaceuticals news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the business's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $456.00, for a total value of $6,384,000.00. Following the completion of the sale, the executive vice president directly owned 37,725 shares of the company's stock, valued at $17,202,600. The trade was a 27.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of the firm's stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total transaction of $28,650,425.20. Following the transaction, the chairman owned 24,026 shares in the company, valued at $10,792,479.20. This represents a 72.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 151,073 shares of company stock valued at $67,326,816 over the last ninety days. Company insiders own 0.20% of the company's stock.</p>
<div class="lb-trans"><p>在 Vertex Pharmaceuticals 的其他新闻中，执行副总裁 Charles F. Wagner, Jr. 于 12 月 3 日出售了 14,000 股公司的股票，交易发生在该日。股票以平均价格 456.00 美元出售，总价值为 6,384,000.00 美元。出售完成后，该执行副总裁直接持有 37,725 股公司的股票，价值 17,202,600 美元。此次交易使其持股减少了 27.07%。该交易已在 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，董事长 Jeffrey M. Leiden 于 12 月 3 日在一笔交易中出售了 63,781 股公司的股票。股票以平均价格 449.20 美元出售，总交易额为 28,650,425.20 美元。交易完成后，董事长在公司持有 24,026 股，价值 10,792,479.20 美元。这代表其持股减少了 72.64%。该销售的 SEC 文件提供了更多信息。过去九十天内，内部人士共出售了价值 67,326,816 美元的 151,073 股公司股票。公司内部人士持有公司股票的 0.20%。</p>
</div><h2>About Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Vertex Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化 (CF) 的疗法。它为至少 2 岁或以上的 CF 患者提供 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者提供 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者提供 ORKAMBI；以及为 1 岁或以上的 CF 患者提供 ivacaftor 的 KALYDECO。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>如何判断一只股票是否支付股息以及何时支付</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了实施阶段</li>
<li>CD 计算器：定期存款计算器</li>
<li>在 10 年期国债利率上升时购买的 3 只金融股票</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场意识到之前购买……而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

B. Riley Wealth Advisors Inc. 购入了 4,141 股福泰制药的股票